The minor histocompatibility antigen HA-3 arises from differential proteasome-mediated cleavage of the lymphoid blast crisis (Lbc) oncoprotein.

Minor histocompatibility (H) antigens crucially affect the outcome of human leukocyte antigen (HLA)-identical allogeneic stem cell transplantation (SCT). To understand the basis of alloimmune responses against minor H antigens, identification of minor H peptides and their antigenicity-determining mechanisms is essential. Here we report the identification of HA-3 and its encoding gene. The HA-3 peptide, VTEPGTAQY (HA-3T), is encoded by the lymphoid blast crisis (Lbc) oncogene. We thus show for the first time that a leukemia-associated oncogene can give rise to immunogenic T-cell epitopes that may have participated in antihost and antileukemic alloimmune responses. Genotypic analysis of HA-3- individuals revealed the allelic counterpart VMEPGTAQY (HA-3M). Despite the lack of T-cell recognition of HA-3- cells, the Thr-->Met substitution had only a modest effect on peptide binding to HLA-A1 and a minimal impact on recognition by T cells when added exogenously to target cells. This substitution did not influence transporter associated with antigen processing (TAP) transport, but, in contrast to the HA-3T peptide, HA-3M is destroyed by proteasome-mediated digestion. Thus, the immunogenicity of minor H antigens can result from proteasome-mediated destruction of the negative allelic peptide.

[1]  S. Brunak,et al.  Prediction of proteasome cleavage motifs by neural networks. , 2002, Protein engineering.

[2]  G. Tamma,et al.  Ht31: the first protein kinase A anchoring protein to integrate protein kinase A and Rho signaling1 , 2001, FEBS letters.

[3]  J. Shabanowitz,et al.  The HA-2 Minor Histocompatibility Antigen Is Derived from a Diallelic Gene Encoding a Novel Human Class I Myosin Protein , 2001, The Journal of Immunology.

[4]  J. Scott,et al.  Akap-lbc Anchors Protein Kinase a and Nucleates G␣ 12 -selective Rho-mediated Stress Fiber Formation* , 2022 .

[5]  K. Hadeler,et al.  PAProC: a prediction algorithm for proteasomal cleavages available on the WWW , 2001, Immunogenetics.

[6]  J. Shabanowitz,et al.  The Immunogenicity of a New Human Minor Histocompatibility Antigen Results from Differential Antigen Processing , 2001, The Journal of experimental medicine.

[7]  S. Carr,et al.  Mass Spectrometry in Biology & Medicine , 2000, Humana Press.

[8]  J. Shabanowitz,et al.  Subfemtomole MS and MS/MS peptide sequence analysis using nano-HPLC micro-ESI fourier transform ion cyclotron resonance mass spectrometry. , 2000, Analytical chemistry.

[9]  C. Kuttler.  An Algorithm for the Prediction of Proteasomal Cleavages , 2000, German Conference on Bioinformatics.

[10]  P M Kloetzel,et al.  Abrogation of CTL Epitope Processing by Single Amino Acid Substitution Flanking the C-Terminal Proteasome Cleavage Site1 , 2000, The Journal of Immunology.

[11]  P. Kloetzel,et al.  Efficient Generation of a Hepatitis B Virus Cytotoxic T Lymphocyte Epitope Requires the Structural Features of Immunoproteasomes , 2000, The Journal of experimental medicine.

[12]  J. Shabanowitz,et al.  Cutting edge: the HLA-A*0101-restricted HY minor histocompatibility antigen originates from DFFRY and contains a cysteinylated cysteine residue as identified by a novel mass spectrometric technique. , 1999, Journal of immunology.

[13]  R. Verdijk,et al.  Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens. , 1999, Blood.

[14]  Takeshi Urano,et al.  Activation of the Lbc Rho Exchange Factor Proto-Oncogene by Truncation of an Extended C Terminus That Regulates Transformation and Targeting , 1999, Molecular and Cellular Biology.

[15]  C. Figdor,et al.  A Human Minor Histocompatibility Antigen Specific for B Cell Acute Lymphoblastic Leukemia , 1999, The Journal of experimental medicine.

[16]  P. Kloetzel,et al.  The Sequence Alteration Associated with a Mutational Hotspot in p53 Protects Cells From Lysis by Cytotoxic T Lymphocytes Specific for a Flanking Peptide Epitope , 1998, The Journal of experimental medicine.

[17]  James Segars,et al.  Characterization of Brx, a novel Dbl family member that modulates estrogen receptor action , 1998, Oncogene.

[18]  J. Shabanowitz,et al.  The minor histocompatibility antigen HA-1: a diallelic gene with a single amino acid polymorphism. , 1998, Science.

[19]  L. Eisenlohr,et al.  Murine Transporter Associated with Antigen Presentation (TAP) Preferences Influence Class I–restricted T Cell Responses , 1997, The Journal of experimental medicine.

[20]  E. Goulmy.  Human minor histocompatibility antigens: new concepts for marrow transplantation and adoptive immunotherapy , 1997, Immunological reviews.

[21]  A. Agulnik,et al.  The HLA-A*0201-restricted H-Y antigen contains a posttranslationally modified cysteine that significantly affects T cell recognition. , 1997, Immunity.

[22]  P M Kloetzel,et al.  A single residue exchange within a viral CTL epitope alters proteasome-mediated degradation resulting in lack of antigen presentation. , 1996, Immunity.

[23]  S. Singhal,et al.  Bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia. , 1996, Bone marrow transplantation.

[24]  R. Truitt,et al.  Principles of graft-vs.-leukemia reactivity. , 1995, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[25]  A. Agulnik,et al.  Human H-Y: a male-specific histocompatibility antigen derived from the SMCY protein. , 1995, Science.

[26]  F Koning,et al.  Identification of a graft versus host disease-associated human minor histocompatibility antigen. , 1995, Science.

[27]  M. Olson,et al.  Direct Involvement of the Small GTP-binding Protein Rho in lbc Oncogene Function (*) , 1995, The Journal of Biological Chemistry.

[28]  M. Feltkamp,et al.  Major differences in transporter associated with antigen presentation (TAP)-dependent translocation of MHC class I-presentable peptides and the effect of flanking sequences. , 1995, Journal of immunology.

[29]  R. Henderson,et al.  Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. , 1994, Science.

[30]  A Sette,et al.  Naturally processed peptides longer than nine amino acid residues bind to the class I MHC molecule HLA-A2.1 with high affinity and in different conformations. , 1994, Journal of immunology.

[31]  David A. Williams,et al.  Novel human oncogene lbc detected by transfection with distinct homology regions to signal transduction products. , 1994, Oncogene.

[32]  A. Bakker,et al.  Tissue distribution of human minor histocompatibility antigens. Ubiquitous versus restricted tissue distribution indicates heterogeneity among human cytotoxic T lymphocyte-defined non-MHC antigens. , 1992, Journal of immunology.

[33]  I. Fraser,et al.  Association of the type II cAMP-dependent protein kinase with a human thyroid RII-anchoring protein. Cloning and characterization of the RII-binding domain. , 1992, The Journal of biological chemistry.

[34]  A. Zwinderman,et al.  EFFECTOR MECHANISMS IN GRAFT‐VERSUS-HOST DISEASE IN RESPONSE TO MINOR HISTOCOMPATIBILITY ANTIGENS: II. EVIDENCE OF A POSSIBLE INVOLVEMENT OF PROLIFERATIVE T CELLS , 1990, Transplantation.

[35]  A. Zwinderman,et al.  EFFECTOR MECHANISMS IN GRAFT‐VERSUS-HOST DISEASE IN RESPONSE TO MINOR HISTOCOMPATIBILITY ANTIGENS: I. ABSENCE OF CORRELATION WITH CYTOTOXIC EFFECTOR CELLS , 1990, Transplantation.

[36]  A. Rimm,et al.  Graft-versus-leukemia reactions after bone marrow transplantation. , 1990, Blood.

[37]  W. Fibbe,et al.  Rejection of bone-marrow graft by recipient-derived cytotoxic T lymphocytes against minor histocompatibility antigens , 1990, The Lancet.

[38]  J. Jorgenson,et al.  Quantitative analysis of individual neurons by open tubular liquid chromatography with voltammetric detection. , 1989, Analytical chemistry.

[39]  R. O'reilly.  Allogenic bone marrow transplantation: current status and future directions. , 1983, Blood.

[40]  R. O'reilly,et al.  Allogeneic Bone Marrow Transplantation : Current Status and Future Directions , 2005 .

[41]  J. J. Rood,et al.  Immunogenetics of human minor histocompatibility antigens: their polymorphism and immunodominance , 2004, Immunogenetics.

[42]  N. Shastri,et al.  Producing nature's gene-chips: the generation of peptides for display by MHC class I molecules. , 2002, Annual review of immunology.

[43]  J. Shabanowitz,et al.  Sequencing the Primordial Soup , 2000 .

[44]  A. Goldberg,et al.  Degradation of cell proteins and the generation of MHC class I-presented peptides. , 1999, Annual review of immunology.

[45]  S. Riddell,et al.  In vivo migration and function of transferred HIV-1-specific cytotoxic T cells , 1999, Nature Medicine.

[46]  John Sidney,et al.  Two distinct HLA-A*0101-specific submotifs illustrate alternative peptide binding modes , 1997, Immunogenetics.

[47]  M. de Bueger,et al.  Acquired tolerance for minor histocompatibility antigens after HLA identical bone marrow transplantation. , 1992, International immunology.

[48]  E. Goulmy.  Minor Histocompatibility antigens in man and their role in transplantation. , 1988 .